Validation of a visual analog scale for assessing cough severity in patients with chronic cough

Introduction: Patients with chronic cough experience considerable burden. The cough severity visual analog scale (VAS) records patients’ assessment of cough severity on a 100-mm linear scale ranging from “no cough” (0 mm) to “worst cough” (100 mm). Although cough severity scales are widely used in c...

Full description

Saved in:
Bibliographic Details
Published inTherapeutic advances in respiratory disease Vol. 15; p. 17534666211049743
Main Authors Martin Nguyen, Allison, Bacci, Elizabeth D., Vernon, Margaret, Birring, Surinder S., Rosa, Carmen La, Muccino, David, Schelfhout, Jonathan
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 2021
SAGE PUBLICATIONS, INC
SAGE Publishing
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Introduction: Patients with chronic cough experience considerable burden. The cough severity visual analog scale (VAS) records patients’ assessment of cough severity on a 100-mm linear scale ranging from “no cough” (0 mm) to “worst cough” (100 mm). Although cough severity scales are widely used in clinical practice and research, their use in patients with refractory or unexplained chronic cough has not been formally validated. Methods: This analysis includes data from a phase 2b randomized controlled trial of the P2X3-receptor antagonist gefapixant for treatment of refractory or unexplained chronic cough (NCT02612610). Cough severity VAS scores were assessed at baseline and Weeks 4, 8, and 12. The cough severity VAS was validated using several outcomes, including the Cough Severity Diary (CSD), Leicester Cough Questionnaire (LCQ), patient global impression of change (PGIC) scale, and objective cough frequency. Validation metrics included test–retest reliability, convergent and known-groups validity, responsiveness, and score interpretation (i.e., clinically meaningful change threshold). Results: The analysis included 253 patients (median age, 61.0 years; females, 76%). Test–retest reliability of the cough severity VAS was moderate (intraclass correlation coefficient, 0.51). The cough severity VAS had acceptable convergent validity with other related measures (Pearson r of 0.53 and -0.41 for CSD and LCQ total scores, respectively; p < 0.0001 for each). Known-groups validity was supported by significant differences in mean cough severity VAS scores across severity groups defined using CSD, LCQ, and cough frequency tertiles. A large effect size was observed in patients with the greatest improvements in PGIC (Cohen d = -1.8). A ⩾ 30-mm reduction in the cough severity VAS was estimated as a clinically meaningful change threshold for clinical trials in chronic cough. Conclusions: The cough severity VAS is a valid and responsive measure. A cough severity VAS reduction of ⩾ 30 mm can discriminate clinically meaningful changes in chronic cough severity in clinical studies.
AbstractList Introduction: Patients with chronic cough experience considerable burden. The cough severity visual analog scale (VAS) records patients’ assessment of cough severity on a 100-mm linear scale ranging from “no cough” (0 mm) to “worst cough” (100 mm). Although cough severity scales are widely used in clinical practice and research, their use in patients with refractory or unexplained chronic cough has not been formally validated. Methods: This analysis includes data from a phase 2b randomized controlled trial of the P2X3-receptor antagonist gefapixant for treatment of refractory or unexplained chronic cough (NCT02612610). Cough severity VAS scores were assessed at baseline and Weeks 4, 8, and 12. The cough severity VAS was validated using several outcomes, including the Cough Severity Diary (CSD), Leicester Cough Questionnaire (LCQ), patient global impression of change (PGIC) scale, and objective cough frequency. Validation metrics included test–retest reliability, convergent and known-groups validity, responsiveness, and score interpretation (i.e., clinically meaningful change threshold). Results: The analysis included 253 patients (median age, 61.0 years; females, 76%). Test–retest reliability of the cough severity VAS was moderate (intraclass correlation coefficient, 0.51). The cough severity VAS had acceptable convergent validity with other related measures (Pearson r of 0.53 and -0.41 for CSD and LCQ total scores, respectively; p < 0.0001 for each). Known-groups validity was supported by significant differences in mean cough severity VAS scores across severity groups defined using CSD, LCQ, and cough frequency tertiles. A large effect size was observed in patients with the greatest improvements in PGIC (Cohen d = -1.8). A ⩾ 30-mm reduction in the cough severity VAS was estimated as a clinically meaningful change threshold for clinical trials in chronic cough. Conclusions: The cough severity VAS is a valid and responsive measure. A cough severity VAS reduction of ⩾ 30 mm can discriminate clinically meaningful changes in chronic cough severity in clinical studies.
INTRODUCTIONPatients with chronic cough experience considerable burden. The cough severity visual analog scale (VAS) records patients' assessment of cough severity on a 100-mm linear scale ranging from "no cough" (0 mm) to "worst cough" (100 mm). Although cough severity scales are widely used in clinical practice and research, their use in patients with refractory or unexplained chronic cough has not been formally validated. METHODSThis analysis includes data from a phase 2b randomized controlled trial of the P2X3-receptor antagonist gefapixant for treatment of refractory or unexplained chronic cough (NCT02612610). Cough severity VAS scores were assessed at baseline and Weeks 4, 8, and 12. The cough severity VAS was validated using several outcomes, including the Cough Severity Diary (CSD), Leicester Cough Questionnaire (LCQ), patient global impression of change (PGIC) scale, and objective cough frequency. Validation metrics included test-retest reliability, convergent and known-groups validity, responsiveness, and score interpretation (i.e., clinically meaningful change threshold). RESULTSThe analysis included 253 patients (median age, 61.0 years; females, 76%). Test-retest reliability of the cough severity VAS was moderate (intraclass correlation coefficient, 0.51). The cough severity VAS had acceptable convergent validity with other related measures (Pearson r of 0.53 and -0.41 for CSD and LCQ total scores, respectively; p < 0.0001 for each). Known-groups validity was supported by significant differences in mean cough severity VAS scores across severity groups defined using CSD, LCQ, and cough frequency tertiles. A large effect size was observed in patients with the greatest improvements in PGIC (Cohen d = -1.8). A ⩾ 30-mm reduction in the cough severity VAS was estimated as a clinically meaningful change threshold for clinical trials in chronic cough. CONCLUSIONSThe cough severity VAS is a valid and responsive measure. A cough severity VAS reduction of ⩾ 30 mm can discriminate clinically meaningful changes in chronic cough severity in clinical studies.
Patients with chronic cough experience considerable burden. The cough severity visual analog scale (VAS) records patients' assessment of cough severity on a 100-mm linear scale ranging from "no cough" (0 mm) to "worst cough" (100 mm). Although cough severity scales are widely used in clinical practice and research, their use in patients with refractory or unexplained chronic cough has not been formally validated. This analysis includes data from a phase 2b randomized controlled trial of the P2X3-receptor antagonist gefapixant for treatment of refractory or unexplained chronic cough (NCT02612610). Cough severity VAS scores were assessed at baseline and Weeks 4, 8, and 12. The cough severity VAS was validated using several outcomes, including the Cough Severity Diary (CSD), Leicester Cough Questionnaire (LCQ), patient global impression of change (PGIC) scale, and objective cough frequency. Validation metrics included test-retest reliability, convergent and known-groups validity, responsiveness, and score interpretation (i.e., clinically meaningful change threshold). The analysis included 253 patients (median age, 61.0 years; females, 76%). Test-retest reliability of the cough severity VAS was moderate (intraclass correlation coefficient, 0.51). The cough severity VAS had acceptable convergent validity with other related measures (Pearson of 0.53 and -0.41 for CSD and LCQ total scores, respectively;  < 0.0001 for each). Known-groups validity was supported by significant differences in mean cough severity VAS scores across severity groups defined using CSD, LCQ, and cough frequency tertiles. A large effect size was observed in patients with the greatest improvements in PGIC (Cohen  = -1.8). A ⩾ 30-mm reduction in the cough severity VAS was estimated as a clinically meaningful change threshold for clinical trials in chronic cough. The cough severity VAS is a valid and responsive measure. A cough severity VAS reduction of ⩾ 30 mm can discriminate clinically meaningful changes in chronic cough severity in clinical studies.
Introduction: Patients with chronic cough experience considerable burden. The cough severity visual analog scale (VAS) records patients’ assessment of cough severity on a 100-mm linear scale ranging from “no cough” (0 mm) to “worst cough” (100 mm). Although cough severity scales are widely used in clinical practice and research, their use in patients with refractory or unexplained chronic cough has not been formally validated. Methods: This analysis includes data from a phase 2b randomized controlled trial of the P2X3-receptor antagonist gefapixant for treatment of refractory or unexplained chronic cough (NCT02612610). Cough severity VAS scores were assessed at baseline and Weeks 4, 8, and 12. The cough severity VAS was validated using several outcomes, including the Cough Severity Diary (CSD), Leicester Cough Questionnaire (LCQ), patient global impression of change (PGIC) scale, and objective cough frequency. Validation metrics included test–retest reliability, convergent and known-groups validity, responsiveness, and score interpretation (i.e., clinically meaningful change threshold). Results: The analysis included 253 patients (median age, 61.0 years; females, 76%). Test–retest reliability of the cough severity VAS was moderate (intraclass correlation coefficient, 0.51). The cough severity VAS had acceptable convergent validity with other related measures (Pearson r of 0.53 and -0.41 for CSD and LCQ total scores, respectively; p  < 0.0001 for each). Known-groups validity was supported by significant differences in mean cough severity VAS scores across severity groups defined using CSD, LCQ, and cough frequency tertiles. A large effect size was observed in patients with the greatest improvements in PGIC (Cohen d  = -1.8). A ⩾ 30-mm reduction in the cough severity VAS was estimated as a clinically meaningful change threshold for clinical trials in chronic cough. Conclusions: The cough severity VAS is a valid and responsive measure. A cough severity VAS reduction of ⩾ 30 mm can discriminate clinically meaningful changes in chronic cough severity in clinical studies.
Author Muccino, David
Martin Nguyen, Allison
Vernon, Margaret
Birring, Surinder S.
Rosa, Carmen La
Schelfhout, Jonathan
Bacci, Elizabeth D.
Author_xml – sequence: 1
  givenname: Allison
  orcidid: 0000-0002-6385-5570
  surname: Martin Nguyen
  fullname: Martin Nguyen, Allison
  organization: Merck & Co., Inc., Kenilworth, NJ, USA
– sequence: 2
  givenname: Elizabeth D.
  surname: Bacci
  fullname: Bacci, Elizabeth D.
  organization: Evidera Inc., Bethesda, MD, USA
– sequence: 3
  givenname: Margaret
  surname: Vernon
  fullname: Vernon, Margaret
  organization: Evidera Inc., Bethesda, MD, USA
– sequence: 4
  givenname: Surinder S.
  surname: Birring
  fullname: Birring, Surinder S.
  organization: Centre for Human & Applied Physiological Sciences, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King’s College London, London, UK
– sequence: 5
  givenname: Carmen La
  surname: Rosa
  fullname: Rosa, Carmen La
  organization: Merck & Co., Inc., Kenilworth, NJ, USA
– sequence: 6
  givenname: David
  surname: Muccino
  fullname: Muccino, David
  organization: Merck & Co., Inc., Kenilworth, NJ, USA
– sequence: 7
  givenname: Jonathan
  surname: Schelfhout
  fullname: Schelfhout, Jonathan
  email: jonathan.schelfhout@merck.com
  organization: Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34697975$$D View this record in MEDLINE/PubMed
BookMark eNp1kkuPFCEUhYkZ4zz0B7gxJG7c9MizKDYmZqLOJJO4UbfkFgXVdKqhhaqezL-XtsZ5aFxBDt85cC_3FB3FFB1Cryk5p1Sp91RJLpqmYZQSoZXgz9DJQVsdxKNH-2N0WsqGEKmJal-g4-rSSit5gswPGEMPU0gRJ48B70OZYcQQYUwDLhZGh33KGEpxpYQ4YJvmYY2L27scplscIt5Vv4tTwTdhWmO7zikGu3Av0XMPY3Gv7tYz9P3zp28Xl6vrr1-uLj5er6zkbFoB4dKptqFcdFZL3ilousZxTpgnyipPtKWtIKQRyklPO2kpV77vGqb6HoCfoaslt0-wMbsctpBvTYJgfgspDwbyFOzoTM-80FIzIUUjenCaguCi1Z4rpiU9ZH1YsnZzt3W9raVlGJ-EPj2JYW2GtDetlIy3rAa8uwvI6efsymS2oVg3jhBdmothsm2EJIKpir79C92kOdfmV6p2gwnVClkpulA2p1Ky8_ePocQcRsH8MwrV8-ZxFfeOP39fgfMFKDC4h2v_n_gLNmy9Kg
CitedBy_id crossref_primary_10_1186_s12890_023_02423_6
crossref_primary_10_1016_j_alit_2024_02_002
crossref_primary_10_1016_j_anai_2022_05_003
crossref_primary_10_1007_s00408_022_00592_5
crossref_primary_10_1016_j_chpulm_2024_100049
crossref_primary_10_1016_j_eclinm_2023_102100
crossref_primary_10_1007_s00408_022_00553_y
crossref_primary_10_1016_j_chest_2024_05_015
crossref_primary_10_1183_23120541_00425_2023
crossref_primary_10_1186_s12890_022_02136_2
crossref_primary_10_3346_jkms_2022_37_e275
crossref_primary_10_2147_COPD_S372991
crossref_primary_10_1016_j_anai_2023_03_032
crossref_primary_10_1183_23120541_00452_2022
crossref_primary_10_1007_s00408_024_00714_1
crossref_primary_10_1002_ppul_26677
crossref_primary_10_3389_fmed_2022_987887
crossref_primary_10_1016_j_alit_2022_05_006
crossref_primary_10_1186_s12931_023_02384_8
crossref_primary_10_5937_Galmed2307034S
crossref_primary_10_1007_s00408_022_00587_2
crossref_primary_10_1001_jama_2023_18035
crossref_primary_10_1007_s00408_023_00621_x
crossref_primary_10_1007_s00408_023_00666_y
crossref_primary_10_1371_journal_pone_0286588
crossref_primary_10_1001_jama_2023_18508
crossref_primary_10_1002_lrh2_10316
crossref_primary_10_1002_rcr2_1323
crossref_primary_10_33549_physiolres_935062
crossref_primary_10_1164_rccm_202211_2128LE
crossref_primary_10_1016_j_anai_2023_12_025
crossref_primary_10_1183_23120541_00279_2022
Cites_doi 10.1183/23120541.00300-2019
10.1183/09031936.00218714
10.1016/j.jcm.2016.02.012
10.1016/j.coph.2015.03.003
10.1183/13993003.01136-2019
10.1016/j.chest.2019.08.001
10.1186/1745-9974-5-5
10.1053/rmed.2001.1195
10.1378/chest.14-2506
10.1016/j.rmed.2012.11.018
10.1183/13993003.01615-2019
10.1016/j.chest.2017.06.024
10.1186/s12890-017-0496-1
10.1007/s00408-015-9701-2
10.1186/s12890-020-1106-1
10.1016/j.jaip.2019.01.049
10.1136/thx.2006.067413
10.1111/resp.13462
10.1197/aemj.10.4.360
10.1007/s00408-019-00258-9
10.1007/s00408-019-00305-5
10.1067/mem.2001.118012
10.1136/thorax.58.4.339
10.1016/S2213-2600(19)30471-0
10.1378/chest.121.4.1123
10.1136/bmjopen-2016-014112
10.1177/1753466620915155
10.1164/rccm.201209-1686OC
10.1016/j.chest.2017.10.016
10.1016/j.jaip.2019.04.012
10.1177/1753465810372526
10.1136/bmjopen-2019-030945
10.1016/j.chest.2017.05.038
ContentType Journal Article
Copyright The Author(s), 2021
The Author(s), 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s), 2021 2021 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
Copyright_xml – notice: The Author(s), 2021
– notice: The Author(s), 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s), 2021 2021 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
DBID AFRWT
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1177/17534666211049743
DatabaseName Sage Journals GOLD Open Access 2024
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE

Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: AFRWT
  name: Sage Journals GOLD Open Access 2024
  url: http://journals.sagepub.com/
  sourceTypes: Publisher
– sequence: 5
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1753-4666
EndPage 17534666211049743
ExternalDocumentID oai_doaj_org_article_d2f4959245464dae91a43489f372951a
10_1177_17534666211049743
34697975
10.1177_17534666211049743
Genre Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Merck Sharp and Dohme
  funderid: https://doi.org/10.13039/100009947
– fundername: ;
GroupedDBID ---
-MK
-TM
01A
0R~
123
29Q
31X
4.4
53G
54M
5VS
7X7
8FI
8FJ
AABMB
AABOD
AADTT
AADUE
AAQDB
AARDL
AARIX
AATBZ
ABAFQ
ABAWP
ABEIX
ABFWQ
ABHQH
ABJIS
ABKRH
ABQXT
ABRHV
ABUWG
ABVFX
ACARO
ACDSZ
ACDXX
ACGFS
ACGZU
ACOFE
ACROE
ACSBE
ACSIQ
ADBBV
ADOGD
ADZZY
AENEX
AEQLS
AERKM
AEUHG
AEUIJ
AEWDL
AEWHI
AEXNY
AFCOW
AFEET
AFKRA
AFKRG
AFRWT
AFUIA
AGNHF
AHHFK
AJUZI
ALIPV
ALJHS
ALMA_UNASSIGNED_HOLDINGS
AOIJS
ARTOV
ASPBG
AVWKF
AZFZN
B8M
B8Z
BCNDV
BDDNI
BENPR
BKSCU
BPHCQ
BSEHC
BVXVI
BYIEH
CAG
CCPQU
CDWPY
CFDXU
COF
CS3
DC-
DC.
DOPDO
DV7
EBS
EJD
EMOBN
F5P
FEDTE
FYUFA
GROUPED_DOAJ
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
HF~
HMCUK
HVGLF
HYE
HZ~
J8X
K.F
M4V
N9A
O9-
OK1
P.B
PIMPY
PQQKQ
ROL
RPM
S01
SFC
SFK
SGV
UKHRP
ZONMY
ZPPRI
ZRKOI
ZSSAH
CGR
CUY
CVF
ECM
EIF
H13
NPM
AASGM
AAYXX
ACRPL
ADYCS
CITATION
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c532t-a035e786134bc953b7a6b6e3302f07c7f09c18400647e5f1b5c137fdb627ddaa3
IEDL.DBID RPM
ISSN 1753-4666
1753-4658
IngestDate Tue Oct 22 15:10:27 EDT 2024
Tue Sep 17 21:24:40 EDT 2024
Sat Aug 17 03:09:25 EDT 2024
Thu Oct 10 18:33:43 EDT 2024
Fri Dec 06 07:33:31 EST 2024
Sat Sep 28 08:20:39 EDT 2024
Tue Jul 16 20:38:49 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords patient-reported outcomes
objective cough frequency
responder threshold
Leicester Cough Questionnaire
idiopathic cough
Cough Severity Diary
cough monitoring
clinically meaningful change
minimal important difference
Language English
License This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c532t-a035e786134bc953b7a6b6e3302f07c7f09c18400647e5f1b5c137fdb627ddaa3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
ORCID 0000-0002-6385-5570
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552382/
PMID 34697975
PQID 2613247845
PQPubID 4450849
ParticipantIDs doaj_primary_oai_doaj_org_article_d2f4959245464dae91a43489f372951a
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8552382
proquest_miscellaneous_2586450427
proquest_journals_2613247845
crossref_primary_10_1177_17534666211049743
pubmed_primary_34697975
sage_journals_10_1177_17534666211049743
PublicationCentury 2000
PublicationDate 2021-00-00
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – year: 2021
  text: 2021-00-00
PublicationDecade 2020
PublicationPlace London, England
PublicationPlace_xml – name: London, England
– name: England
– name: Thousand Oaks
– name: Sage UK: London, England
PublicationTitle Therapeutic advances in respiratory disease
PublicationTitleAlternate Ther Adv Respir Dis
PublicationYear 2021
Publisher SAGE Publications
SAGE PUBLICATIONS, INC
SAGE Publishing
Publisher_xml – name: SAGE Publications
– name: SAGE PUBLICATIONS, INC
– name: SAGE Publishing
References Çolak, Nordestgaard, Laursen 2017; 152
Spinou, Birring 2014; 6
Song, Chang, Faruqi 2015; 45
Vernon, Kline Leidy, Nacson 2009; 5
Martin Nguyen, Muccino, Birring 2019; 143
Arinze, de Roos, Karimi 2020; 6
Martin Nguyen, Bacci, Dicpinigaitis 2020; 14
Bird, Dickson 2001; 38
Yousaf, Montinero, Birring 2013; 107
Zhan, Zhang, Jiang 2020; 20
McGarvey, Birring, Morice 2020; 56
Boulet, Coeytaux, McCrory 2015; 147
Smith, Kitt, Butera 2020; 55
Brightling, Monterio, Green 2001; 95
Mukaka 2012; 24
Eccles 2020; 198
Morice, Millqvist, Bieksiene 2020; 55
Kang, Won, Lee 2019; 197
Koo, Li 2016; 15
Birring, Brew, Kilbourn 2017; 7
Lee, Matos, Evans 2013; 187
Chamberlain, Garrod, Douiri 2015; 193
French, Irwin, Fletcher 2002; 121
Smith, Allman, Badri 2020; 157
Irwin, French, Chang 2018; 153
McGarvey, Gibson 2019; 7
Koo, Jeong, Kim 2019; 24
Decalmer, Webster, Kelsall 2007; 62
French, Crawford, Bova 2017; 152
Koskela, Lätti, Purokivi 2017; 17
Koskela, Lätti, Pekkanen 2019; 9
Cho, Birring, Fletcher 2019; 7
Garza, Wyrwich 2003; 10
Vernon, Kline Leidy, Nacson 2010; 4
Birring, Prudon, Carr 2003; 58
Smith, Kitt, Morice 2020; 8
Birring, Spinou 2015; 22
bibr22-17534666211049743
bibr35-17534666211049743
bibr7-17534666211049743
Cohen J. (bibr30-17534666211049743) 1988
bibr2-17534666211049743
bibr38-17534666211049743
bibr25-17534666211049743
bibr12-17534666211049743
bibr15-17534666211049743
bibr5-17534666211049743
bibr32-17534666211049743
Mukaka MM. (bibr27-17534666211049743) 2012; 24
bibr33-17534666211049743
bibr20-17534666211049743
bibr10-17534666211049743
bibr9-17534666211049743
bibr13-17534666211049743
bibr36-17534666211049743
bibr23-17534666211049743
bibr26-17534666211049743
Spinou A (bibr18-17534666211049743) 2014; 6
bibr3-17534666211049743
bibr19-17534666211049743
bibr16-17534666211049743
bibr6-17534666211049743
Martin Nguyen A (bibr28-17534666211049743) 2019; 143
bibr14-17534666211049743
bibr8-17534666211049743
bibr17-17534666211049743
McGarvey L (bibr29-17534666211049743) 2020; 56
bibr24-17534666211049743
bibr34-17534666211049743
bibr37-17534666211049743
bibr4-17534666211049743
bibr31-17534666211049743
bibr21-17534666211049743
bibr11-17534666211049743
bibr1-17534666211049743
References_xml – volume: 45
  start-page: 1479
  year: 2015
  end-page: 1481
  article-title: The global epidemiology of chronic cough in adults: a systematic review and meta-analysis
  publication-title: Eur Respir J
  contributor:
    fullname: Faruqi
– volume: 24
  start-page: 69
  year: 2012
  end-page: 71
  article-title: Statistics corner: a guide to appropriate use of correlation coefficient in medical research
  publication-title: Malawi Med J
  contributor:
    fullname: Mukaka
– volume: 153
  start-page: 196
  year: 2018
  end-page: 209
  article-title: Classification of cough as a symptom in adults and management algorithms: CHEST guideline and expert panel report
  publication-title: Chest
  contributor:
    fullname: Chang
– volume: 55
  start-page: 1901136
  year: 2020
  article-title: ERS guidelines on the diagnosis and treatment of chronic cough in adults and children
  publication-title: Eur Respir J
  contributor:
    fullname: Bieksiene
– volume: 198
  start-page: 13
  year: 2020
  end-page: 21
  article-title: The powerful placebo effect in cough: relevance to treatment and clinical trials
  publication-title: Lung
  contributor:
    fullname: Eccles
– volume: 14
  start-page: 1753466620915155
  year: 2020
  article-title: Quantitative measurement properties and score interpretation of the Cough Severity Diary in patients with chronic cough
  publication-title: Ther Adv Respir Dis
  contributor:
    fullname: Dicpinigaitis
– volume: 38
  start-page: 639
  year: 2001
  end-page: 643
  article-title: Clinically significant changes in pain along the visual analog scale
  publication-title: Ann Emerg Med
  contributor:
    fullname: Dickson
– volume: 157
  start-page: 111
  year: 2020
  end-page: 118
  article-title: The neurokinin-1 receptor antagonist orvepitant is a novel antitussive therapy for chronic refractory cough: results from a phase 2 pilot study (VOLCANO-1)
  publication-title: Chest
  contributor:
    fullname: Badri
– volume: 121
  start-page: 1123
  year: 2002
  end-page: 1131
  article-title: Evaluation of a cough-specific quality-of-life questionnaire
  publication-title: Chest
  contributor:
    fullname: Fletcher
– volume: 10
  start-page: 360
  year: 2003
  end-page: 363
  article-title: Health utility measures and the standard gamble
  publication-title: Acad Emerg Med
  contributor:
    fullname: Wyrwich
– volume: 55
  start-page: 1901615
  year: 2020
  article-title: Gefapixant in two randomised dose-escalation studies in chronic cough
  publication-title: Eur Respir J
  contributor:
    fullname: Butera
– volume: 62
  start-page: 329
  year: 2007
  end-page: 334
  article-title: Chronic cough: how do cough reflex sensitivity and subjective assessments correlate with objective cough counts during ambulatory monitoring?
  publication-title: Thorax
  contributor:
    fullname: Kelsall
– volume: 24
  start-page: 551
  year: 2019
  end-page: 557
  article-title: Development and validation of the COugh Assessment Test (COAT)
  publication-title: Respirology
  contributor:
    fullname: Kim
– volume: 15
  start-page: 155
  year: 2016
  end-page: 163
  article-title: A guideline of selecting and reporting intraclass correlation coefficients for reliability research
  publication-title: J Chiropr Med
  contributor:
    fullname: Li
– volume: 6
  start-page: 00300
  year: 2020
  end-page: 2019
  article-title: Prevalence and incidence of, and risk factors for chronic cough in the adult population: the Rotterdam Study
  publication-title: ERJ Open Res
  contributor:
    fullname: Karimi
– volume: 152
  start-page: 563
  year: 2017
  end-page: 573
  article-title: Risk factors for chronic cough among 14,669 individuals from the general population
  publication-title: Chest
  contributor:
    fullname: Laursen
– volume: 197
  start-page: 635
  year: 2019
  end-page: 639
  article-title: Impact of cough and unmet needs in chronic cough: a survey of patients in Korea
  publication-title: Lung
  contributor:
    fullname: Lee
– volume: 143
  year: 2019
  article-title: Defining minimal clinically important differences (MCID) in chronic cough: analyses of objective cough counts from a phase 2 randomized controlled trial
  publication-title: et al. J Allergy Clin Immunol
  contributor:
    fullname: Birring
– volume: 6
  start-page: S728
  year: 2014
  end-page: S734
  article-title: An update on measurement and monitoring of cough: what are the important study endpoints?
  publication-title: J Thorac Dis
  contributor:
    fullname: Birring
– volume: 4
  start-page: 199
  year: 2010
  end-page: 208
  article-title: Measuring cough severity: development and pilot testing of a new seven-item cough severity patient-reported outcome measure
  publication-title: Ther Adv Respir Dis
  contributor:
    fullname: Nacson
– volume: 187
  start-page: 991
  year: 2013
  end-page: 997
  article-title: A longitudinal assessment of acute cough
  publication-title: Am J Respir Crit Care Med
  contributor:
    fullname: Evans
– volume: 20
  start-page: 68
  year: 2020
  article-title: A new simple score of chronic cough: cough evaluation test
  publication-title: BMC Pulm Med
  contributor:
    fullname: Jiang
– volume: 17
  start-page: 146
  year: 2017
  article-title: Long-term prognosis of chronic cough: a prospective, observational cohort study
  publication-title: BMC Pulm Med
  contributor:
    fullname: Purokivi
– volume: 147
  start-page: 804
  year: 2015
  end-page: 814
  article-title: Tools for assessing outcomes in studies of chronic cough: CHEST guideline and expert panel report
  publication-title: Chest
  contributor:
    fullname: McCrory
– volume: 58
  start-page: 339
  year: 2003
  end-page: 343
  article-title: Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ)
  publication-title: Thorax
  contributor:
    fullname: Carr
– volume: 152
  start-page: 547
  year: 2017
  end-page: 562
  article-title: Change in psychological, physiological, and situational factors in adults after treatment of chronic cough
  publication-title: Chest
  contributor:
    fullname: Bova
– volume: 5
  start-page: 5
  year: 2009
  article-title: Measuring cough severity: perspectives from the literature and from patients with chronic cough
  publication-title: Cough
  contributor:
    fullname: Nacson
– volume: 9
  start-page: e030945
  year: 2019
  article-title: Risk factors for repetitive doctor’s consultations due to cough: a cross-sectional study in a Finnish employed population
  publication-title: BMJ Open
  contributor:
    fullname: Pekkanen
– volume: 95
  start-page: 999
  year: 2001
  end-page: 1002
  article-title: Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability
  publication-title: Respir Med
  contributor:
    fullname: Green
– volume: 8
  start-page: 775
  year: 2020
  end-page: 785
  article-title: Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial
  publication-title: Lancet Respir Med
  contributor:
    fullname: Morice
– volume: 22
  start-page: 37
  year: 2015
  end-page: 40
  article-title: How best to measure cough clinically
  publication-title: Curr Opin Pharmacol
  contributor:
    fullname: Spinou
– volume: 193
  start-page: 401
  year: 2015
  end-page: 408
  article-title: The impact of chronic cough: a cross-sectional European survey
  publication-title: Lung
  contributor:
    fullname: Douiri
– volume: 56
  start-page: 3800
  year: 2020
  article-title: Late breaking abstract-two phase 3 randomized clinical trials of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough (COUGH-1 and COUGH-2)
  publication-title: Eur Respir J
  contributor:
    fullname: Morice
– volume: 107
  start-page: 408
  year: 2013
  end-page: 412
  article-title: The long term outcome of patients with unexplained chronic cough
  publication-title: Respir Med
  contributor:
    fullname: Birring
– volume: 7
  start-page: e014112
  year: 2017
  article-title: Rococo study: a real-world evaluation of an over-the-counter medicine in acute cough (a multicentre, randomised, controlled study)
  publication-title: BMJ Open
  contributor:
    fullname: Kilbourn
– volume: 7
  start-page: 1715
  year: 2019
  end-page: 1723
  article-title: Methods of cough assessment
  publication-title: J Allergy Clin Immunol Pract
  contributor:
    fullname: Fletcher
– volume: 7
  start-page: 1711
  year: 2019
  end-page: 1714
  article-title: What is chronic cough? Terminology
  publication-title: J Allergy Clin Immunol Pract
  contributor:
    fullname: Gibson
– ident: bibr4-17534666211049743
  doi: 10.1183/23120541.00300-2019
– ident: bibr3-17534666211049743
  doi: 10.1183/09031936.00218714
– ident: bibr26-17534666211049743
  doi: 10.1016/j.jcm.2016.02.012
– volume: 56
  start-page: 3800
  year: 2020
  ident: bibr29-17534666211049743
  publication-title: Eur Respir J
  contributor:
    fullname: McGarvey L
– ident: bibr17-17534666211049743
  doi: 10.1016/j.coph.2015.03.003
– ident: bibr2-17534666211049743
  doi: 10.1183/13993003.01136-2019
– ident: bibr15-17534666211049743
  doi: 10.1016/j.chest.2019.08.001
– ident: bibr16-17534666211049743
  doi: 10.1186/1745-9974-5-5
– ident: bibr32-17534666211049743
  doi: 10.1053/rmed.2001.1195
– ident: bibr35-17534666211049743
  doi: 10.1378/chest.14-2506
– ident: bibr11-17534666211049743
  doi: 10.1016/j.rmed.2012.11.018
– volume: 143
  year: 2019
  ident: bibr28-17534666211049743
  publication-title: et al.
  contributor:
    fullname: Martin Nguyen A
– ident: bibr14-17534666211049743
  doi: 10.1183/13993003.01615-2019
– ident: bibr7-17534666211049743
  doi: 10.1016/j.chest.2017.06.024
– ident: bibr10-17534666211049743
  doi: 10.1186/s12890-017-0496-1
– ident: bibr6-17534666211049743
  doi: 10.1007/s00408-015-9701-2
– ident: bibr34-17534666211049743
  doi: 10.1186/s12890-020-1106-1
– ident: bibr19-17534666211049743
  doi: 10.1016/j.jaip.2019.01.049
– ident: bibr31-17534666211049743
  doi: 10.1136/thx.2006.067413
– ident: bibr33-17534666211049743
  doi: 10.1111/resp.13462
– ident: bibr38-17534666211049743
  doi: 10.1197/aemj.10.4.360
– ident: bibr8-17534666211049743
  doi: 10.1007/s00408-019-00258-9
– ident: bibr36-17534666211049743
  doi: 10.1007/s00408-019-00305-5
– ident: bibr37-17534666211049743
  doi: 10.1067/mem.2001.118012
– ident: bibr20-17534666211049743
  doi: 10.1136/thorax.58.4.339
– ident: bibr13-17534666211049743
  doi: 10.1016/S2213-2600(19)30471-0
– ident: bibr21-17534666211049743
  doi: 10.1378/chest.121.4.1123
– ident: bibr24-17534666211049743
  doi: 10.1136/bmjopen-2016-014112
– ident: bibr23-17534666211049743
  doi: 10.1177/1753466620915155
– volume: 6
  start-page: S728
  year: 2014
  ident: bibr18-17534666211049743
  publication-title: J Thorac Dis
  contributor:
    fullname: Spinou A
– ident: bibr25-17534666211049743
  doi: 10.1164/rccm.201209-1686OC
– volume-title: Statistical power analysis for the behavioral sciences
  year: 1988
  ident: bibr30-17534666211049743
  contributor:
    fullname: Cohen J.
– ident: bibr1-17534666211049743
  doi: 10.1016/j.chest.2017.10.016
– ident: bibr12-17534666211049743
  doi: 10.1016/j.jaip.2019.04.012
– volume: 24
  start-page: 69
  year: 2012
  ident: bibr27-17534666211049743
  publication-title: Malawi Med J
  contributor:
    fullname: Mukaka MM.
– ident: bibr22-17534666211049743
  doi: 10.1177/1753465810372526
– ident: bibr9-17534666211049743
  doi: 10.1136/bmjopen-2019-030945
– ident: bibr5-17534666211049743
  doi: 10.1016/j.chest.2017.05.038
SSID ssj0059078
Score 2.4688275
Snippet Introduction: Patients with chronic cough experience considerable burden. The cough severity visual analog scale (VAS) records patients’ assessment of cough...
Patients with chronic cough experience considerable burden. The cough severity visual analog scale (VAS) records patients' assessment of cough severity on a...
Introduction: Patients with chronic cough experience considerable burden. The cough severity visual analog scale (VAS) records patients’ assessment of cough...
INTRODUCTIONPatients with chronic cough experience considerable burden. The cough severity visual analog scale (VAS) records patients' assessment of cough...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
sage
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 17534666211049743
SubjectTerms Chronic Disease
Cough - diagnosis
Cough - drug therapy
Cough - etiology
Female
Humans
Middle Aged
Original Research
Quality of Life
Reproducibility of Results
Surveys and Questionnaires
Validity
Visual Analog Scale
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LSxxBEC6CB8lFook68UEHAoIwONOP6Z6jiiIBc4rB29BP3MusZHf9_amanl1dVHLJdbp7KKqmp77qqv4K4HvS3AfLfWmCUaU0rSmdVKJEz4zxlvHJOrqcfPuzubmTP-7V_YtWX1QTlumBs-LOAk-I4TFKULKRwca2tlLgOxPlm1SdoVHFl8FU_gcrDPnMmMMkeiWio5QI1CnakYigxZoXGsj630KYrwslX1R7DQ7o-hNsjciRnWeJt-FD7Hdg83bMjX-G7jdC6twhiU0Ts-xpMlvgAtvT-QyboTEiQ4jK7JDnRZfFPLXoYegbI7WwY5OejTSrM0bns8xn5tw87wvcXV_9urwpx_YJpVeCz0tbCRW1QX8tnW-VcNo2rolCVDxV2utUtZ7iO7puGlWqnfK10Cm4husQrBW7sNFP-7gPLBhhESh641Ilk3AWN2vwIUhlomlsW8DpUp3dY2bJ6OqRSPyV7gu4IIWvJhLB9fAAzd6NZu_-ZfYCDpfm6sZdN-swGkR8qI1UBXxbDeN-oSSI7eN0gXOUaaSiDiMF7GXrriRBOVvdalyt1-y-Jur6SD95GDi5jcKI3vACTugLeRbpXS18_R9aOICPnGpshiOhQ9iY_1nEIwRJc3c87Ie_W6YKZg
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9QwDLdgSIgXtI2vsg0FCQkJqaJtkiZ9QoCYpknjiaF7q_IJ99Ju6x1_P3aau3Ea8JoPNbWd-Gc7sQHeRNU4bxpXaq9lKXSnSyskL1Ezo72lXTSWHidffG3PLsX5Qi6yw23K1yo3Z2I6qP3oyEf-HpE-6n6lhfxwdV1S1SiKruYSGvfhQd2gKkd5VoutwSXR8EtP4RR9HFVtjmpSwiVqEwjdyf4RiKn5jl5K6fv_hjnvXp384_5XUkmn-_A4Y0n2cWb-AdwLwyE8vMjR8ifQf0eQPddMYmNkhv1aTmucYAby2LAJ2RMYglZmUuQXlRhzVLSHobYMVNSOLQeWE69OjDy2zM25dOdxT-Hy9Mu3z2dlLqhQOsmbVWkqLoPSSElhXSe5Vaa1beC8amKlnIpV58jioweoQcbaSldzFb1tG-W9MfwZ7A3jEF4A85obhI5O21iJyK3B7eud90LqoFvTFfBuQ87-as6b0dc5tfgd2hfwiQi-HUgpr1PDePOjzzuo901EYw7NRSla4U3oaiM4ClekwKOsTQHHG3b1eR9O_a3UFPB62407iMIiZgjjGsdI3QpJNUcKeD5zd7sSXGenOoWz1Q7fd5a62zMsf6Ys3Vqija-bAt6ShNwu6Z9UePn_HziCRw3dp0nun2PYW92swwkCopV9laT-N5WwBQ8
  priority: 102
  providerName: ProQuest
– databaseName: Sage Journals GOLD Open Access 2024
  dbid: AFRWT
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9RAEB_qFcQX8dtolRUEQYhNsrvZzZNU8ShCfZBW-xb2U--hifQugv-9M8nm9GgFX5NdMszuZH7zDfAyqsp5U7lcey1zoRudWyF5jpoZ7S3torFUnHzyqT4-Ex_P5fke9HMtTOLg-g2lVSFF48-apJu80YcpyHhI7SUFAm-yXgQiYv522Fy0k7t7nqpBTyg-PVxQaNtRQuSvfC5vuwH7lUJNtYD9o-Xnr6fzz1uirThWzymiF7-QAqHXfnRHlY0d_6-DqVezLf9KGRu12PIO3E7wkx1N9-Uu7IXuHtw8SQH2-9B-QVw-jVlifWSG_VytB9xgOnLysDWeaGCIc5kZg8Wo95ijOT8MFWygOXhs1bHUq3XNyMnL3NR-d1r3AM6WH07fH-dpBkPuJK82uSm4DEqj0hfWNZJbZWpbB86LKhbKqVg0joxEqlkNMpZWupKr6G1dKe-N4Q9h0fVdeAzMa24QbTptYyEitwYl3jvvhdRB16bJ4PXMzvbH1GqjLVM38iu8z-AdMXy7kLpkjw_6y29tErrWVxHtP7QwpaiFN6EpjeB4HyPFKmVpMjiYj6udL16LJiWCTKWFzODF9jUKHUVSTBf6AddIXQtJY0oyeDSd7pYSpLNRjcLdaufcd0jdfdOtvo-NvbWUiKCqDF7RDflD0j-58OS_Vz6FWxVl44zOowNYbC6H8Azh1MY-TyLwG4RPGLo
  priority: 102
  providerName: SAGE Publications
Title Validation of a visual analog scale for assessing cough severity in patients with chronic cough
URI https://journals.sagepub.com/doi/full/10.1177/17534666211049743
https://www.ncbi.nlm.nih.gov/pubmed/34697975
https://www.proquest.com/docview/2613247845
https://search.proquest.com/docview/2586450427
https://pubmed.ncbi.nlm.nih.gov/PMC8552382
https://doaj.org/article/d2f4959245464dae91a43489f372951a
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_aDsZexr7nrQsaDAYDN4klWfJjWxrKIKWUdsub0WcXWJ3SJPv7dyfbWUO3lz0FZBkL3V3u99Od7gA-RVU4bwqXa69lLnSlcyskz9EzI9_SLhpLl5OnZ-Xplfg6k7MdkP1dmJS07-z8oPl5c9DMf6TcytsbN-zzxIbn02MtkT7pYrgLu-h-e4re_v1KZHvp_puiL6J_7UKZVGWJxgTidSI9AoE0NdHBgUpVlGZ4zy-l8v1_w5wPUyfv5X8llzR5Bk87LMkO2zU_h53QvIDH0y5a_hLqbwiy255JbBGZYb_myzW-YBo6sWFLFE9gCFqZSZFfdGLMUdMeht4yUFM7Nm9YV3h1yejElrm2lm477xVcTU4uj0_zrqFC7iQvVrkZcRmURg8urKskt8qUtgycj4o4Uk7FUeWI8dEF1CDj2Eo35ip6WxbKe2P4a9hrFk14C8xrbhA6Om3jSERuDZqvd94LqYMuTZXBl34769u2bkY97kqLPxBDBke04ZuJVPI6DSzurutO8LUvIpI5pItSlMKbUI2N4KhckQKPcmwy2O_FVXd2uKyRHyJiVFrIDD5uHqMFUVjENGGxxjlSl0JSz5EM3rTS3ayk144M1Jbct5a6_QSVNlXp7pQ0g8-kIX-W9M9dePff33gPTwpKtUknQ_uwt7pbhw-IlVZ2gBYyUwN4dDi5-H6Jv0cnZ-cXg3TyMEh28xsJ2RM-
link.rule.ids 230,314,727,780,784,864,885,2102,4024,12056,21388,21966,27853,27923,27924,27925,31719,31720,33744,33745,43310,43805,44945,45333,53791,53793
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED9BJwEviG8CA4yEhIQUkcR27DwhhjYVWCuENrS3yJ_Ql3QsLX8_d4nbUQ14TRzVvfP5fndn_w7gVVSV86ZyufZa5kI3OrdC8hw9M8Zb2kVj6XLybF5PT8WnM3mWEm59Ola52ROHjdovHeXI3yLSR9-vtJDvzn_m1DWKqquphcZ12CPmdDmBvYPD-Zevm71YYug3XIZT9PPobFNdkyiX6JlA8E4RkEBUzXc800Dg_zfUefXw5B8nwAandHQHbic0yd6P6r8L10J3D27MUr38PrTfEGaPXZPYMjLDfi36NX5gOsrZsB4VFBjCVmaG2i-6MeaobQ9DfxmorR1bdCxRr_aMcrbMjWy647gHcHp0ePJhmqeWCrmTvFrlpuAyKI2yFNY1kltlalsHzosqFsqpWDSOYj66ghpkLK10JVfR27pS3hvDH8KkW3bhMTCvuUHw6LSNhYjcGjRg77wXUgddmyaDNxtxtucjc0ZbJnLxK7LP4IAEvh1IpNfDg-XF9zbZUOuriOEcBoxS1MKb0JRGcFxekUqPsjQZ7G_U1SZL7NvLdZPBy-1rtCEqjJguLNc4RupaSOo6ksGjUbvbmeA8G9Uo_Frt6H1nqrtvusWPgadbS4zydZXBa1ohl1P6pxSe_P8PvICb05PZcXv8cf75Kdyq6HTNkAzah8nqYh2eITxa2efJBn4DfwsJZQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED_BkCZeEN8EBhgJCQkpaxLbsfMIg2p8dNoDQ3uL_DkqsbRaW_5-7py0tBq88Go7suU7534_3_kO4HVUlfOmcrn2WuZCNzq3QvIcLTPyLe2isfQ4eXJSH5-Jz-fyfKvUVwrad3Z62P28POymP1Js5fzSjdZxYqPTyZGWSJ90NZr7OLoJtyRHJVsT9f4nLJHzpVdwiuZFKzs4NCnXErUJRO1EfQTCaSqlgw2NaijYcMs6pST-f0Oe1wMot6LAkmEa34U7A6Jk7_qV34MbobsP-5PBZ_4A2u8ItfvKSWwWmWG_posVfmA6urdhCxRSYAhdmUn-XzRlzFHpHoY2M1BpOzbt2JB-dcHo3pa5PqNuP-4hnI0_fjs6zoeyCrmTvFrmpuAyKI12XFjXSG6VqW0dOC-qWCinYtE44n30DDXIWFrpSq6it3WlvDeGP4K9btaFJ8C85gYBpNM2FiJya_AQe-e9kDro2jQZvF1vZzvvs2e05ZBg_JoYMnhPG74ZSImvU8Ps6qIdxN_6KiKlQ9IoRS28CU1pBEcVi-R-lKXJ4GAtrnY4jYsWWSLiRqWFzODVphvPETlHTBdmKxwjdS0kVR7J4HEv3c1K1tqRgdqR-85Sd3tQdVOu7kFVM3hDGvJnSf_chaf_PcdL2D_9MG6_fjr58gxuVxR7k66KDmBvebUKzxE8Le2LdEx-A5kQEok
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Validation+of+a+visual+analog+scale+for+assessing+cough+severity+in+patients+with+chronic+cough&rft.jtitle=Therapeutic+advances+in+respiratory+disease&rft.au=Martin+Nguyen%2C+Allison&rft.au=Bacci%2C+Elizabeth+D.&rft.au=Vernon%2C+Margaret&rft.au=Birring%2C+Surinder+S.&rft.date=2021&rft.issn=1753-4666&rft.eissn=1753-4666&rft.volume=15&rft_id=info:doi/10.1177%2F17534666211049743&rft.externalDBID=n%2Fa&rft.externalDocID=10_1177_17534666211049743
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1753-4666&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1753-4666&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1753-4666&client=summon